Zevra net income drops 88.29% to $8.8 million in Q2 FY26; revenue rises 53% to $39.7 million

Reuters2026/08/05 20:53

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zevra Therapeutics posted Q2 2026 revenue of $39.7 million, up 53% from Q2 2025.
Net income fell to $8.8 million; diluted EPS declined to $0.14.
MIPLYFFA net revenue was $30.2 million; global Expanded Access Program reimbursements were $9 million.
Cash, cash equivalents and investments totaled $260.2 million at June 30, 2026.
CEO Neil F. McFarlane cited strong U.S. commercial execution; Zevra requested EU re-examination of its arimoclomol marketing application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9804382) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zevra net income drops 88.29% to $8.8 million in Q2 FY26; revenue rises 53% to $39.7 million

You may also like

Crypto prices